How body composition affects prostate cancer treatment
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how body composition (amount of muscle and fat) affects the way a radioactive therapy called 177Lu-PSMA works for prostate cancer. By understanding this, doctors hope to personalize the dose for each patient, making the treatment more effective and safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be male and 18 years or older
- Must have prostate cancer confirmed by a biopsy (prostatic adenocarcinoma) and a doctor has decided to treat it with 177Lu-PSMA therapy
- Must have a PSMA PET/CT scan showing that the cancer cells have a specific marker called PSMA, which the treatment targets
- Must be able to understand the study and follow its rules
- Must have health insurance (affiliated with a social security scheme)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.